Michael Galitz, MD
Endocrinology, Diabetes & Metabolism · Mobile, ALNPI 1275503690
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 524 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 17.5% — the pattern of someone who eats at a lot of different presentations.
Across 524 payments — averaging $18.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$2K
- Novo Nordisk$1K
- Dexcom, Inc.$830
- Bayer$643
- Amgen$495
- Xeris Pharmaceuticals, Inc.$491
- plus $4K from 31 others
What the payments were for
- Food & beverage$9,503100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 90 | $1,667 |
| Novo Nordisk | 89 | $1,151 |
| Dexcom, Inc. | 67 | $830 |
| Bayer | 33 | $643 |
| Amgen(2 entities) | 17 | $495 |
| Xeris Pharmaceuticals, Inc. | 20 | $491 |
| Sanofi-aventis U.S. LLC | 23 | $436 |
| Boehringer Ingelheim | 23 | $430 |
| BETA Bionics, Inc. | 11 | $402 |
| Antares Pharma, Inc. | 14 | $387 |
| Corcept Therapeutics | 19 | $348 |
| Abbott | 14 | $267 |
| Novartis | 18 | $228 |
| AbbVie | 10 | $214 |
| AstraZeneca(2 entities) | 11 | $196 |
| Amarin Pharma, Inc. | 8 | $152 |
| Tandem Diabetes Care, Inc. | 8 | $148 |
| Insulet Corporation | 7 | $140 |
| Medtronic | 3 | $110 |
| Rhythm Pharmaceuticals, Inc. | 5 | $108 |
| IBSA Pharma Inc. | 5 | $95 |
| Amryt Pharma Holdings Ltd | 4 | $85 |
| Radius Health, Inc. | 3 | $74 |
| Recordati_rare_diseases_inc. | 3 | $61 |
| Chiesi USA, Inc. | 2 | $47 |
| Amneal Pharmaceuticals LLC | 2 | $41 |
| Sequel Med Tech, LLC | 2 | $39 |
| Kyowa Kirin, Inc. | 2 | $38 |
| Mannkind Corporation | 2 | $36 |
| Pfizer | 2 | $30 |
| GSK | 1 | $23 |
| EUSA Pharma (US) LLC | 1 | $20 |
| Halozyme Inc | 1 | $19 |
| Ascendis Pharma Endocrinology Inc | 1 | $19 |
| Astellas Pharma US Inc | 1 | $18 |
| Averitas Pharma Inc. | 1 | $15 |
| Esperion Therapeutics, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- iLet Bionic Pancreas$353
- TEPEZZA$145
- NOCDURNA$131
- XYOSTED$131
- JARDIANCE$125
- Ozempic$122
- EVENITY$122
- MOUNJARO$121
- iLet Insulin Infusion Kit Inset$118
- iLet Insulin Infusion Kit Contact Detach$118
- DEXCOM G6 TRANSMITTER$108
How this compares
$9,515 in reported general payments places this provider in the 60th percentile of 79 endocrinology, diabetes & metabolism providers in Alabama.
See all endocrinology, diabetes & metabolism providers in Alabama →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 139 | $170,760 |
| JardianceEmpagliflozin | 136 | $144,617 |
| TrulicityDulaglutide | 46 | $81,218 |
| MounjaroTirzepatide | 53 | $61,188 |
| Tresiba Flextouch U-200Insulin Degludec | 49 | $51,209 |
| FarxigaDapagliflozin Propanediol | 46 | $40,318 |
| Tresiba Flextouch U-100Insulin Degludec | 36 | $30,877 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 34 | $26,870 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 13 | $23,037 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 17 | $21,003 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 20 | $17,056 |
| VascepaIcosapent Ethyl | 20 | $13,205 |
| Humalog Kwikpen U-100Insulin Lispro | 32 | $9,546 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 42 | $7,917 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 14 | $7,120 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $1,151 | $176,456164 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $430 | $171,487170 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $1,667 | $146,733111 claims |
| AstraZenecaFarxiga | $196 | $40,31846 claims |
| AbbVieSynthroid | $214 | $2,81826 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $41 | $2,574123 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 79 endocrinology, diabetes & metabolism providers in Alabama.
Other endocrinology, diabetes & metabolism in Mobile
- Wilburn BoltonMobile$52K
- Anita KemmerlyMobile$13K
- Michael DavisMobile$12K
- Heather FishelMobile$11K
- Jocelyn HewittMobile$9K
- Huey McDanielMobile$8K
- Stephen DavisMobile$7K
- Ross del FierroMobile$6K
- Jessica BhathalMobile$6K
- Neil SchaffnerOpelika$642K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.